552c7ae14ClaimIn England, estimated financial costs from adverse childhood experiences were £37.8 billion for mental illness and £22.7 billion for smoking, while in Wales each accounted for £1.8 billion.AgreeDisagree
552c7ae14ClaimThe American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptomsAgreeDisagree
552c7ae14ClaimThe Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.AgreeDisagree
552c7ae14ClaimCompass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.AgreeDisagree
552c7ae14ClaimTreatment-resistant depression is estimated to affect approximately 4 million people in the U.S., with fewer than 5% receiving a treatment indicated for the condition.AgreeDisagree
552c7ae14ClaimA survey commissioned by Compass Pathways revealed that nearly two in three caregivers report treatment-resistant depression impacts family health, with over half experiencing a major toll on their own mental health.AgreeDisagree
552c7ae14ClaimA survey commissioned by Compass Pathways found that nearly 95% of individuals living with treatment-resistant depression describe themselves as functioning but struggling, surviving day-to-day, or barely getting by.AgreeDisagree
552c7ae14ClaimCanada should exclude mental illness as a sole condition for medically assisted dyingAgreeDisagree
552c7ae14ClaimOutro plans to use its $7 million in capital to expand its network of deprescribing clinicians and develop artificial intelligence clinical decision support tools.AgreeDisagree
552c7ae14ClaimApproximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.AgreeDisagree
552c7ae14ClaimOutro's deprescribing platform incorporates personalized hyperbolic tapering plans, compounded medication doses, patient monitoring, and specially-trained clinicians.AgreeDisagree
552c7ae14ClaimOutro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.AgreeDisagree
552c7ae14ClaimHyperbolic tapering is the most effective protocol for discontinuing psychiatric medicationsAgreeDisagree
552c7ae14ClaimCommercial digital platforms are suitable for managing complex psychiatric drug withdrawalAgreeDisagree
552c7ae14ClaimU.S. healthcare providers should prioritize deprescribing over long-term psychiatric medication maintenanceAgreeDisagree
552c7ae14ClaimFDA approval standards based on short-term trials adequately protect long-term antidepressant usersAgreeDisagree
552c7ae14ClaimVictoria should launch targeted public health campaigns on cannabis risks for young womenAgreeDisagree
552c7ae14ClaimCannabis-related admissions create an unsustainable strain on Victoria's public health systemAgreeDisagree
552c7ae14ClaimCannabis consumption poses a severe public health risk through induced psychosisAgreeDisagree
552c7ae14ClaimA NHS report into mental health services following Suzanne Brown's killing identified eight failures, including a lack of risk assessments or professional monitoring after Jake Neate's clozapine was stopped.AgreeDisagree